LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Analysts

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $35.40.

Separately, HC Wainwright reissued a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday, November 7th.

LENZ Therapeutics Price Performance

LENZ Therapeutics stock traded down $0.10 during midday trading on Monday, reaching $26.69. The company's stock had a trading volume of 99,082 shares, compared to its average volume of 158,953. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The stock's 50 day simple moving average is $28.87 and its 200 day simple moving average is $26.87.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the company posted ($1.33) EPS. As a group, analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Trading of LENZ Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of LENZ Therapeutics during the 4th quarter worth approximately $29,000. SG Americas Securities LLC acquired a new stake in LENZ Therapeutics during the 3rd quarter valued at $107,000. China Universal Asset Management Co. Ltd. purchased a new position in LENZ Therapeutics during the fourth quarter worth $168,000. Squarepoint Ops LLC acquired a new position in shares of LENZ Therapeutics in the second quarter worth $181,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of LENZ Therapeutics in the third quarter valued at $182,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.